Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Add-on curcumin nanomicelle beneficial in rheumatoid arthritis treatment

04 Oct 2019

The addition of curcumin nanomicelle to the treatment regimen of patients with rheumatoid arthritis (RA) positively influences several outcomes, although not meaningfully, as shown in a trial.

A total of 65 RA patients were randomized to receive either a curcumin nanomicelle 40 mg (n=30) or placebo (n=35) capsule three times a day for 12 weeks. Researchers measured the Disease Activity Score of 28 joints (DAS‐28) and erythrocyte sedimentation rate (ESR) at baseline and after 12 weeks.

Results showed that DAS‐28, tender joint count (TJC) and swollen joint count (SJC) improved substantially from baseline at the end of treatment in both the curcumin and placebo groups. There were no significant between-group differences seen in the magnitude of change, as well as in baseline values. Nonetheless, the improvements were numerically greater in the active treatment group.

No significant changes were documented in ESR between the two treatment groups.

A major extraction derived from turmeric, curcumin possesses excellent antitumour, antimicrobial and antioxidant properties. However, the substance has poor bioavailability owing to its poor solubility, poor absorption, rapid metabolism and quick systemic elimination, all of which limits its therapeutic effect in vivo. To resolve these limitations, various nanomicelles have been used to construct a protective structure, which works both to prolong its circulation inside the body and to enhance its solubility. [ACS Appl Mater Interfaces 2018;10:23595-23604]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.